12 Jun 2019
Clot-busting drug may affect stroke patients’ immune system: study
by Anne Crawford
A study by Monash University’s Australian Centre for Blood Diseases (ACBD) into a drug commonly used to remove blot clots in stroke suggests it may weaken the immune system.
The study, published in Frontiers in Immunology, found that t-PA (tissue-type
plasminogen activator) affected several aspects related to the immune system in a mouse model of acute ischemic stroke (AIS). Ischemic stroke is caused when a blood vessel supplying blood to the brain is obstructed by a clot, and accounts for 80 per cent of all types of stroke. It is a leading cause of disability and mortality worldwide.
A study by Monash University’s Australian Centre for Blood Diseases (ACBD) into a drug commonly used to remove blot clots in stroke suggests it may weaken the immune system.
The study, published in Frontiers in Immunology, found that t-PA (tissue-type
plasminogen activator) affected several aspects related to the immune system in a mouse model of acute ischemic stroke (AIS). Ischemic stroke is caused when a blood vessel supplying blood to the brain is obstructed by a clot, and accounts for 80 per cent of all types of stroke. It is a leading cause of disability and mortality worldwide.
3MT Comp Winners!
CCS Competition winner Lakshanie Wickramasinghe |
CCS Recent Publications: 27th May - 10th June 2019
Recent publications for Central Clinical School feature affiliated authors in the following departments:
- MAPrc
- ACBD
- Anaesthesia & Perioperative Medicine
- Neuroscience
- Diabetes
- Melbourne Sexual Health Centre
- Immunology & Pathology
- Gastroenterology
- Surgery
Subscribe to:
Posts (Atom)